Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure

Annals of Oncology

Volumn 11, Issue 1, 2000, Pages 85-89

  Martin M ^a   Lluch, A ^b   Casado, A ^a   Carbonero, I García ^a   De Paz, L ^b   Esteban, C ^a   Insa, A ^b   Alfonso, R ^a   Garcia Conde J ^b   Diaz Rubio, E ^a,b  

^a University Hospital of Madrid   (Spain)

^b University Hospitals of Valencia   (Spain)

Author keywords

Breast cancer; Combination therapy; Paclitaxel; Vinorelbine

Indexed keywords

ANTHRACYCLINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; RECURRENCE; SAFETY; TIME FACTORS; VINBLASTINE;

EID: 0033961907     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008374425246     Document Type: Article

References (22)

1. Hortobagyi GN. Treatment of Breast Cancer. N Engl J Med 1998; 339: 974-84.
2. Fossati R, Confalonieri C. Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of publishing randomized trials involving 31,510 women. J Clin Oncol 1998; 16: 3439-60.
3. Wiserman L, Spencer CM. Paclitaxel: An update of its use in the treatment of metastatic breast cancer and ovarian and other gynaecological cancers. Drugs Aging 1998; 12: 305-34.
4. Smith GA. Current status of vinorelbine for breast cancer. Oncology 1995; 9: 767-73.
5. Jones S, Winer E, Vogel C et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13: 2567-74.
6. Nabholtz JM, Thuerlimann B, Bezwoda WR et al. Taxotere improves survival over mytomicin C vinblastine in patients with metastatic breast cancer who have failed an anthracycline containing regimen: Final results of a phase II randomized trial. Proc ASCO 1998; 17: 390 (Abstr).
7. Nabolhtz JM, Gelman K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-67.
8. Seidman AD, Tiersten A, Hudis C et al. Phase II trial of paclitaxel by three-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575-81.
9. Knic VC, Eberwein DJ, Miller CG. Vinorelbine tartrate and paclitaxel combinations: Enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 1995; 87: 1072-7.
10. Photiou A, Shah P, Leone LK et al. In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer 1997; 33: 463-70.
11. Culine S, Roch I, Pinguet F. Combination paclitaxel and vinorelbine therapy: In vitro cytotoxic interactions and dose-escalation study in patients with anthracycline-resistant metastatic breast cancer. Proc ASCO 1998; 17: 515 (Abstr).
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
13. Hainsworth JD, Greco FA. Paclitaxel administered by one-hour infusion: Preliminary results of a phase I II trial comparing two schedules. Cancer 1994; 74: 1377-82.
14. Livingston RB, Ellis GK, Gralow JR et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997; 15: 1395-400.
15. Michelotti A, Gennari A, Salvadori B et al. Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: A phase II study. Ann Oncol 1996; 7: 857-60.
16. Romero Acuña L, Langhi M, Perez J et al. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 1999; 17: 74-81.
17. Ibrahim N, Hortobagyi GN, Valero V et al. Phase I study of vinorelbine and paclitaxel by simultaneous three-hour infusion for untreated metastatic breast cancer. Proc AACR 1995; 36: 1443 (Abstr).
18. Gardin G, Pronzato P, Tognoni A et al. A phase II trial of vinorelbine and paclitaxel in patients with metastatic breast cancer who have failed prior anthracycline containing chemotherapy. Proc ASCO 1998; 17: 542 (Abstr).
19. Jaremtchuk A, Matwiejuk M, Polera O et al. Feasibility study of the combination Navelbine and paclitaxel in advanced breast cancer. Proc ASCO 1997; 16: 614 (Abstr).
20. Ellis GK, Gralow JR, Pierce HI et al. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgastrim for metastatic breast cancer: High complete response rate in a phase I II study of doxorubicin-treated patients J Clin Oncol 1999; 17: 1407-12.
21. Tortiorello A, Fachini G, Caponigro F et al. Phase I II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 1998; 47: 91-7.
22. Cocconi G, Mambrini A, Vasini G et al. Vinorelbine combined with paclitaxel, administered in a continuous 96-hour i.v. infusion in pretreated advanced breast cancer patients. Proc ASCO 1998; 17: 800 (Abstr).